FBFredeswinda Romero Bueno

Fredeswinda Romero Bueno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fredeswinda Romero Bueno has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late

    by Miguel Górgolas Hernández-Mora, Alfonso Cabello Úbeda, Laura Prieto Pérez, Felipe Villar Álvarez, Beatriz Álvarez Álvarez, María Jesús Rodríguez Nieto, Irene Carrillo Acosta, Itziar Fernández Ormaechea, Aws Waleed Mohammed Al-Hayani, Pilar Carballosa, et al.

    Summary: Introduction: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease. Methods: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020. Findings: A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001). Interpretation: The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support. Funding: None.


  • Open Access

    Visual versus automatic ultrasound scoring of lung B-lines: reliability and consistency between systems

    by Jorge Short, Carlos Acebes, Guido Rodriguez-De-Lema, Giuliana Maria Concetta La Paglia, Maria Pavón, Olga Sánchez-Pernaute, Julio Cesar Vazquez, Fredeswinda Romero-Bueno, Jesús Garrido, Esperanza Naredo

    Aims. To evaluate the agreement between a visual and an automatic counting system of lung B-lines by ultrasound (US) as well as to test the inter- and intra-observer reliability of both systems in patients with lung diseases.Material and methods. We included four patients with different lung conditions. Four ultrasonographers expert in lung US blindly, independently and consecutively performed, in two rounds, a US B-mode assessment of 8 lung intercostal spaces of each patient. Each US assessment consisted of a visual and an automatic counting of B-lines.Results. Agreement between visual and automatic counting of B-lines was good to excellent [intraclass correlation coefficient (ICC) 0.79-0.84, p<0.001]. Intra-observer reliability was good to excellent [ICC 0.62-0.99, p<0.001] except for one investigator in whom it was close to moderate for the automatic system [ICC 0.49, p<0.05]. Inter-observer reliability was excellent for both systems in both rounds [ICC 0.86-0.90, p<0.001].Conclusions. US automatic counting was consistent with US visual counting of lung B-lines, as performed by experts in the field. Both systems showed a high intra- and interobserver reliability.


  • Open Access

    Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits

    by Fi Romero, Mj Martínez‐Calatrava, O Sánchez‐Pernaute, O Gualillo, R Largo, G Herrero‐Beaumont

    BACKGROUND AND PURPOSE Non‐steroidal anti‐inflammatory drugs improve inflammatory cachexia in several conditions. Thus, we have explored inhibition of cyclooxygenase‐2 (COX‐2) in an experimental model of rheumatoid cachexia in rabbits.EXPERIMENTAL APPROACH Chronic arthritis was induced in immunized rabbits by repeated intra‐articular injections of ovalbumin. To increase the degree of systemic inflammation and also to induce atherosclerotic lesions, the animals were fed a hyperlipidaemic diet (2% cholesterol and 6% peanut oil) and were given an endothelial injury of the femoral artery. Rabbits were randomized to receive the COX‐2 inhibitor celecoxib (10 mg·kg−1·day−1) or no treatment. After 4 weeks, sera, peripheral mononuclear cells and vessel specimens were collected.KEY RESULTS Inhibition of COX‐2 by celecoxib modulated the systemic inflammatory response and increased total cholesterol and triglyceride levels. Celecoxib also minimized weight loss and prevented serum albumin fall. At a vascular level, celecoxib reduced COX‐2 protein in the femoral arterial wall, but did not modify size or the macrophage infiltration of femoral lesions nor the percentage of rabbits with spontaneous aortic plaques.CONCLUSIONS AND IMPLICATIONS Our animal model induced a severe inflammatory cachexia, comparable to that of persistently active rheumatoid arthritis. The inhibition of COX‐2 by celecoxib improves this state, suggesting that COX products play an important role in its development, without affecting the development or the progression of vascular lesions. Overall, these results suggest that celecoxib might be considered as a new therapeutic tool for the treatment of rheumatoid cachexia.